Schrödinger Reports 16% Revenue Growth to $54.8 Million in Q2 2025

Schrödinger, Inc. reported a total revenue of $54.8 million for the second quarter of 2025, marking a 16% increase from $47.3 million in the same period last year. The company's software products and services generated $40.5 million, up 15% year-over-year, while drug discovery revenues rose 19% to $14.2 million. For the first half of 2025, total revenues reached $114.3 million, a 36% increase compared to $83.9 million in the first half of 2024. Despite this revenue growth, Schrödinger reported a net loss of $43.2 million for the second quarter, an improvement from a loss of $54.0 million in the prior year.

The company experienced significant changes in its cost structure, with total cost of revenues increasing by 79% to $28.6 million in the second quarter, driven by higher personnel and cloud computing expenses. This resulted in a gross profit of $26.2 million, down from $31.3 million a year earlier, reflecting a gross margin decline from 66% to 48%. Operating expenses also decreased by 6% to $79.1 million, primarily due to a reduction in research and development costs, which fell by 15% to $43.1 million.

Strategically, Schrödinger has been active in expanding its drug discovery collaborations, including a significant agreement with Novartis Pharma AG, which includes an upfront payment of $150 million and potential milestone payments totaling up to $2.272 billion. The company is also advancing its proprietary drug discovery programs, with ongoing clinical trials for its MALT1 inhibitor, SGR-1505, and CDC7 inhibitor, SGR-2921. The FDA has granted Fast Track designation for both compounds, indicating their potential significance in treating specific cancers.

Operationally, Schrödinger's workforce was reduced by approximately 60 employees, or 7% of its total staff, as part of a restructuring effort aimed at improving cash burn and operational efficiency. The company reported cash, cash equivalents, and marketable securities totaling $462.3 million as of June 30, 2025, which it believes will be sufficient to fund operations for at least the next 24 months. The company anticipates continued investment in its software and drug discovery activities, while also exploring additional collaborations and out-licensing opportunities to maximize the potential of its proprietary programs.

Looking ahead, Schrödinger remains focused on leveraging its computational platform to enhance drug discovery and expand its market presence. The company expects to continue facing challenges related to operating losses and cash flow, but is optimistic about the potential for future revenue growth driven by its collaborations and proprietary drug candidates.